These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23989794)

  • 1. HIV: Efficacy through BibNAbs.
    Flemming A
    Nat Rev Drug Discov; 2013 Sep; 12(9):666. PubMed ID: 23989794
    [No Abstract]   [Full Text] [Related]  

  • 2. Bispecific antibodies directed to CD4 domain 2 and HIV envelope exhibit exceptional breadth and picomolar potency against HIV-1.
    Pace CS; Song R; Ochsenbauer C; Andrews CD; Franco D; Yu J; Oren DA; Seaman MS; Ho DD
    Proc Natl Acad Sci U S A; 2013 Aug; 110(33):13540-5. PubMed ID: 23878231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1.
    Moshoette T; Ali SA; Papathanasopoulos MA; Killick MA
    Retrovirology; 2019 Nov; 16(1):31. PubMed ID: 31703699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific Antibodies Against HIV.
    Montefiori DC
    Cell; 2016 Jun; 165(7):1563-1564. PubMed ID: 27315470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct HIV-1 Neutralization Potency Profiles of Ibalizumab-Based Bispecific Antibodies.
    Song R; Pace C; Seaman MS; Fang Q; Sun M; Andrews CD; Wu A; Padte NN; Ho DD
    J Acquir Immune Defic Syndr; 2016 Dec; 73(4):365-373. PubMed ID: 27792681
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.
    Huang Y; Yu J; Lanzi A; Yao X; Andrews CD; Tsai L; Gajjar MR; Sun M; Seaman MS; Padte NN; Ho DD
    Cell; 2016 Jun; 165(7):1621-1631. PubMed ID: 27315479
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protective Efficacy of Broadly Neutralizing Antibodies with Incomplete Neutralization Activity against Simian-Human Immunodeficiency Virus in Rhesus Monkeys.
    Julg B; Sok D; Schmidt SD; Abbink P; Newman RM; Broge T; Linde C; Nkolola J; Le K; Su D; Torabi J; Pack M; Pegu A; Allen TM; Mascola JR; Burton DR; Barouch DH
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antiviral Therapy by HIV-1 Broadly Neutralizing and Inhibitory Antibodies.
    Zhang Z; Li S; Gu Y; Xia N
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad and potent bispecific neutralizing antibody gene delivery using adeno-associated viral vectors for passive immunization against HIV-1.
    Li S; Qiao Y; Jiang S; Wang B; Kong W; Shan Y
    J Control Release; 2021 Oct; 338():633-643. PubMed ID: 34509584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoglobulin isotype influences affinity and specificity.
    Casadevall A; Janda A
    Proc Natl Acad Sci U S A; 2012 Jul; 109(31):12272-3. PubMed ID: 22826242
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical Trials of Broadly Neutralizing Monoclonal Antibodies for Human Immunodeficiency Virus Prevention: A Review.
    Mahomed S; Garrett N; Baxter C; Abdool Karim Q; Abdool Karim SS
    J Infect Dis; 2021 Feb; 223(3):370-380. PubMed ID: 32604408
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD4 binding loop responsible for the neutralization of human monoclonal neutralizing antibody Y498.
    Cao W; Li B; Liu H; Cheng X; Liu Y; Zhao X; Qiao Y
    Virus Res; 2020 Aug; 285():198001. PubMed ID: 32413370
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies.
    Davis-Gardner ME; Alfant B; Weber JA; Gardner MR; Farzan M
    mBio; 2020 Jan; 11(1):. PubMed ID: 31937648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progress toward active or passive HIV-1 vaccination.
    Escolano A; Dosenovic P; Nussenzweig MC
    J Exp Med; 2017 Jan; 214(1):3-16. PubMed ID: 28003309
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vivo protection by broadly neutralizing HIV antibodies.
    van Gils MJ; Sanders RW
    Trends Microbiol; 2014 Oct; 22(10):550-1. PubMed ID: 25169020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neutralizing antibodies take a swipe at HIV in vivo.
    Montefiori DC
    Nat Med; 2005 Jun; 11(6):593-4. PubMed ID: 15937465
    [No Abstract]   [Full Text] [Related]  

  • 17. HIV-1 neutralization coverage is improved by combining monoclonal antibodies that target independent epitopes.
    Doria-Rose NA; Louder MK; Yang Z; O'Dell S; Nason M; Schmidt SD; McKee K; Seaman MS; Bailer RT; Mascola JR
    J Virol; 2012 Mar; 86(6):3393-7. PubMed ID: 22258252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 19. Passive immunization with HIV-1-neutralizing antibodies: is it effective and safe?
    Nittayananta W
    Oral Dis; 2016 Sep; 22(6):460-2. PubMed ID: 27009613
    [No Abstract]   [Full Text] [Related]  

  • 20. Model for competition from self during passive immunization, with application to broadly neutralizing antibodies for HIV.
    Ali Tabei SM; Li Y; Weigert M; Dinner AR
    Vaccine; 2012 Jan; 30(3):607-13. PubMed ID: 22119591
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.